Clinician-to-Clinician Update Clinician-to-Clinician Update

Cancer Care Specialty Updates

July 2017

— Masonic Cancer Center, University of Minnesota. Photo by Brady Willette.

Presurgical radiotherapy shown to help manage myxoid liposarcoma

Presurgical radiologic therapy produces a treatment response in myxoid liposarcomas of the extremities, according to a recent University of Minnesota study. Analysis of outcomes from 11 patients showed that radiotherapy before surgery, while not reducing tumor volume, led to a marked response; 2 patients had a complete response. The finding indicates that presurgical radiotherapy should be considered for management of myxoid liposarcoma and may aid surgical resection. Results were presented at the annual meeting of the American Society of Therapeutic Radiation Oncology last year. Christian M. Ogilvie, MD; Edward Y. Cheng, MD; Denis R. Clohisy, MD; Jianling Yuan, MD, PhD; Kathryn Dusenbery, MD; and L. Chinsoo Cho, MD, MS contributed.

Tissue bank advances study of osteosarcoma and soft-tissue sarcomas

Patients who have had osteosarcoma are being sought to donate blood and tumor tissue samples to the Biology of Osteosarcoma (BOOST) Registry and Biobank, part of a national research effort to encourage and advance study of the disorder. University of Minnesota Health oncologist Brenda Weigel, MD, MSc. leads the regional effort in the development of the repository, which will allow for long-term storage of the osteosarcoma-related biological materials needed in research. Specimens will be made available to qualified researchers to further understanding of the biology of osteosarcoma and to help correlate results with patients’ clinical data. Participants will submit presurgical blood samples, tumor tissue, and follow-up samples to the tissue bank. A similar tissue bank is planned for other soft tissue sarcomas. For information, contact Brenda Weigel, MD, MSc.

Recruitment for trial of soft-tissue tumor therapies opens

University of Minnesota will serve as a site for a National Cancer Institutesponsored trial of therapies for softtissue sarcomas, including liposarcomas. Patients with newly diagnosed soft-tissue sarcoma (non-rhabdomyosarcoma) are being sought as participants in the multisite phase II, III trial. The drugs under review work in different ways to stop tumor growth, and the study seeks to understand whether radiation therapy works better when given with or without combination chemotherapy or pazopanib hydrochloride. Emily Greengard, MD, is the principal investigator.

Legacy of Support

University of Minnesota Health Cancer Care is proud to sponsor the annual sarcoma-support fundraiser Party in the Park, happening on Monday, July 24, 2017, and organized by Rein in Sarcoma. A long-time partner to University of Minnesota Health physicians, the Minnesota foundation Rein in Sarcoma has donated more than $ 1.7 million to fund sarcoma research at Masonic Cancer Center, University of Minnesota over the past 17 years. These seed grants have also leveraged more than $ 7.1 million in additional grants.

University of Minnesota Health physicians and researchers have been active members of the foundation’s board of directors and have served on its committees. Denis Clohisy, MD, serves as a current board member. Under the direction of Kathryn Dusenbery, MD, Rein in Sarcoma launched the Sarcoma Scholars program, which funds 4 second- and third-year medical students who have an interest in sarcoma research. M Health physicians have also helped create Red Flags of Sarcoma, a program to educate the public about the warning signs of sarcomas.

Rein in Sarcoma publishes a Sarcoma Patient Starter Notebook. Developed in partnership with M Health providers and staff and now in its 6th edition, this notebook is a comprehensive guide for newly diagnosed sarcoma patients and is available at no charge to sarcoma patients throughout North America. The foundation also provides “Totes for Hope” bags to patients who are starting chemotherapy treatment at University of Minnesota Health locations and their families.

Related Articles

July 2017

New Approaches to Managing Difficult-to-Treat Sarcomas

Sarcomas, including liposarcoma, present treatment challenges. Recent studies, however, are uncovering the possible benefits of presurgical radiotherapy and new methods for better identifying treatment.

Continue reading

July 2017

Neoadjuvant Radiotherapy for Myxoid Liposarcoma Shows Pathologic Response

Radiotherapy prior to surgery produces clinical benefit for a patient with liposarcoma, rendering the tumor nonviable. Management of his condition required local and systemic treatments.

Continue reading